New subq immunoglobulin formulation safe, effective for primary immunodeficiency disease | ESID

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway 

  • A new subcutaneous immunoglobulin (SCIG) 20% showed a low rate of adverse events and was well tolerated in patients with primary immunodeficiency disease (PID) at infusion volumes of up to 60 mL/site and infusion rates of up to 60 mL/h/site. 

Why this matters 

  • The formulation a...